Phase 1 Success: Cybin's Deuterated DMT Compounds CYB004 and SPL028 Show Promising Results

Clinical-stage biopharmaceutical company Cybin Inc. has reported encouraging results from its Phase 1 trials of two proprietary deuterated DMT molecules, CYB004 and SPL028, aimed at treating generalized anxiety disorder. The trials, conducted on healthy volunteers, showed that both intravenous (IV) and intramuscular (IM) administration routes were safe and well-tolerated. Notably, the IM dosing of SPL028 produced significant, short-duration psychedelic effects in the majority of subjects, suggesting a potential for a convenient and patient-friendly dosing method.

The study found that CYB004, when administered IV, demonstrated stronger psychedelic effects at lower plasma concentrations compared to native DMT, with a rapid onset and duration of approximately 40 minutes. This indicates the potential for a scalable treatment that could be administered over a shorter period than other psychedelics. The positive findings from these trials support the progression to a Phase 2 study in Generalized Anxiety Disorder (GAD), expected to commence in the first quarter of 2024.

Cybin's patent portfolio includes 40 granted patents and over 170 pending applications, with 25 patents directly related to the deuterated DMT program. The company is committed to developing innovative psychedelic-based treatments to address the significant unmet need for new mental health therapies.

Cybin's CEO, Doug Drysdale, expressed enthusiasm for the data, highlighting the potential of IM administration to offer a more convenient and effective dosing option. Dr. Amir Inamdar, Cybin's Chief Medical Officer, emphasized the importance of the Phase 1 studies in advancing the clinical development of the deuterated DMT program and the identification of a dose that could lead to therapeutic efficacy.

The company's goal is to create safe and effective psychedelic-based therapeutics for mental health conditions, supported by a network of renowned partners and scientists. Cybin is also developing CYB003, a deuterated psilocybin analog for major depressive disorder, and maintains a research pipeline of investigational psychedelic-based compounds.

Cybin, founded in 2019 and headquartered in Canada, operates in several countries, including the United States, the United Kingdom, the Netherlands, and Ireland. The company's mission is to revolutionize mental healthcare through the development of new treatment options for mental health conditions, with a focus on proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches.

It is important to note that Cybin does not make medical, treatment, or health benefit claims about its proposed products, and the efficacy of such products has not been confirmed by approved research. The company emphasizes the need for rigorous scientific research and clinical trials to validate the potential benefits of its compounds.